Santiago de Compostela, Spain
Santiago de Compostela, Spain

The University of Santiago de Compostela - USC is a public university located in the city of Santiago de Compostela, Galicia, Spain. A second campus is located in Lugo, Galicia. It is one of the world's oldest universities in continuous operation.The university traces its roots back to 1495, when a school was opened in Santiago. In 1504, Pope Julius II approved the foundation of a university in Santiago but "the bull for its creation was not granted by Clement VII until 1526". In 1555 the institute began to separate itself from strictly religious instruction with the help of Cardinal Juan Álvarez de Toledo and started to work towards developing other academic fields, including the emerging science fields.Today the university's facilities cover more than 1,300,000 square meters . In terms of human resources, the university has more than 2,000 teachers involved in study and research, over 42,000 students, and more than 1,000 people working in administration and services. Moreover, in 2009, the University received the accreditation of Campus of International Excellence by the Ministry of Education , recognising USC as one of the most prestigious universities in Spain.The university ranks 5th in Spain's best universities ranking by Complutense University of Madrid and IAIF and 4th amongst public universities. Wikipedia.


Time filter

Source Type

Patent
Sanofi S.A. and University of Santiago de Compostela | Date: 2015-06-12

Nanocapsule systems of at least one active pharmaceutical ingredient selected from the group consisting of at least one insulin, insulin analogue, insulin derivative, glucagon-like peptide-1 receptor agonist (GLP1 R agonist) and/or dual GLP-1 receptor/glucagon receptor agonist and/or or any combination thereof are disclosed.


Patent
Fundacion Pedro Barrie De La Maza, Sergas, University of Santiago de Compostela, Fundacion Ramon Dominguez and Biomerix | Date: 2015-04-30

The present invention relates to a composition for modulating tumor cell dissemination, in particular metastatic cancer cells. In particular, the invention relates to an agent for modulating metastatic tumor cell dissemination for use in the treatment and/or prevention of a metastatic cancer wherein the agent an extracellular matrix (ECM) protein carried on a polycarbonate polyurethane matrix. The invention also relates to a product, comprising an agent for modulating metastatic tumor cell dissemination, and to a method of treatment or prevention of cancer.


Patent
University of Vigo and University of Santiago de Compostela | Date: 2017-01-11

The present invention refers to pyridazin-3(2H)-one derivatives of general structure I, II and III, which are selective MAO-B inhibitors, and to the use thereof for preparing pharmaceutical compositions intended to treat disorders derived from MAO-B hyperactivity, particularly degenerative disorders of the central nervous system (CNS), such as Parkinsons disease (PD), Alzheimers disease (AD) and other dementias. These are pyridazin-3(2H)-one derivatives having dithiocarbamate moieties bonded to position 4, 5 or 6 through an alkyl chain of variable length (n=1, 2, 3). This invention is also directed to the preparation of said compounds.


Patent
University of Santiago de Compostela | Date: 2017-01-04

The invention relates to a method and a system for struvite crystallization of in order to recover phosphates in urban or industrial wastewater preferably having phosphate concentrations higher than 50 mg P/L, more preferably higher than 100 mg P/L, where phosphates are recovered by means of the crystallization thereof in the form of struvite granules, the diameter of which can reach up to 5 mm. The struvite crystallization system is formed by a crystallizer (1), a decanter (2) with a distribution system (9), and a unit for adding industrial magnesium hydroxide (3). The phosphates are recovered from the wastewater as a result of two steps : a step of growing struvite granules, and a step of growing fine struvite crystals.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: INFRAIA-1-2014-2015 | Award Amount: 10.00M | Year: 2016

ENSAR2 is the integrating activity for European nuclear scientists who are performing research in three of the major subfields defined by NuPECC: Nuclear Structure and Dynamics, Nuclear Astrophysics and Nuclear Physics Tools and Applications. It proposes an optimised ensemble of Networking (NAs), Joint Research (JRAs) and Transnational Access Activities (TAs), which will ensure qualitative and quantitative improvement of the access provided by the current ten infrastructures, which are at the core of this proposal. The novel and innovative developments that will be achieved by the RTD activities will also assure state-of-the-art technology needed for the new large-scale projects. Our community of nuclear scientists profits from the diverse range of world-class research infrastructures all over Europe that can supply different ion beams and energies and, with ELI-NP, high-intensity gamma-ray beams up to 20 MeV. We have made great effort to make the most efficient use of these facilities by developing the most advanced and novel equipment needed to pursue their excellent scientific programmes and applying state-of-the-art developments to other fields and to benefit humanity (e.g. archaeology, medical imaging). Together with multidisciplinary and application-oriented research at the facilities, these activities ensure a high-level socio-economic impact. To enhance the access to these facilities, the community has defined a number of JRAs, using as main criterion scientific and technical promise. These activities deal with novel and innovative technologies to improve the operation of the facilities. The NAs of ENSAR2 have been set-up with specific actions to strengthen the communities coherence around certain resarch topics and to ensure a broad dissemination of results and stimulate multidisciplinary, application-oriented research and innovation at the Research Infrastructures.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: RUR-10-2016-2017 | Award Amount: 2.00M | Year: 2017

Agroforestry (AF) is the practice of deliberately integrating woody vegetation (trees or shrubs) with crop and/or animal systems to benefit from the resulting ecological and economic interactions. Research activities developed by AFINET partners indicates that appropriate application of AF principles and practices is a key avenue to help the European Union to achieve more sustainable methods of food and fibre production, producing both profits for farmers and environmental benefits. However up to now exists a lack of AF knowledge among end-users that prevent the correct implementation of these practices. In this sense AFINET will act at EU level in order to take up research results into agricultural practice, improving knowledge exchange between scientists and practitioners on AF activities, with a special focus on silvoarable and silvopastoral systems design, management, and production and profitability. To achieve this objective AFINET consortium proposes an innovative methodology based on: (i) The creation of a EU reservoir of scientific and practical knowledge of AF with an end-user-friendly access (the Knowledge Cloud). (ii) The creation of a European Interregional network (composed of Regional Agroforestry Innovation Networks - RAINs) considering a multi-actor approach (including farmers, policy makers, advisory services, extension services, etc.), and articulated through the figure of the Innovation Broker. These RAINs groups will be interconnected in nine strategic regions of Europe from Spain, UK, Belgium, Portugal, Italy, Hungary, Poland, France and Finland, representing different climatic, geographical, social, and cultural conditions at European level. In addition, to create a greater user acceptance of the collected solutions and an intensive dissemination to end-users, AFINET will be linked to other networks, initiatives and policy instruments at regional, national and European level with a specific focus on the EIP-AGRI implementation.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMBP-10-2016 | Award Amount: 6.00M | Year: 2017

The overall objective of B-SMART is: 1. to design modular nanoparticles, 2. to manufacture them via a quality-by-design protocol, 3. to achieve delivery of therapeutic RNAs to the brain and treat neurodegenerative diseases. I. To design modular nanoparticles consisting of o an active RNA payload o established (lipid-based), emerging (trigger-responsive polymer-based) or exploratory (extracellular vesicle-based) nanoparticles o a targeting ligand consisting of the variable domain of heavy chain only antibodies (also known as VHHs or nanobodies), which are coupled to the carrier platform II. To manufacture the modular nanoparticles using a microfluidic assembly system that will ensure quality-by-design: uniform nanoparticles across research sites and excellent control over the physico-chemical parameters. III. To test pre-clinical activity of formulations with promising in vitro activity with good cell/blood compatibility and to select the best RNA-formulation for clinical translation to treat neurodegenerative diseases. Pre-clinical efficacy is tested after o local injection o nasal administration o systemic administration The neurodegenerative diseases carry a high burden for patients since they are without exception progressive. But they also carry a substantial socio-economic burden with estimated costs of 130 billion euro. per year (2008). IV. The technical work in B-SMART will be supported by project management. It ensures that the project is coordinated in a clear, unambiguous and mutually acceptable manner and that the project achieves its objectives, within the given financial and time constraints. in B-SMART we expect to arrive at a scale-able nanoparticle formulation with uniform characteristics that shows strong pre-clinical evidence of therapeutic efficacy and is ready for clinical translation.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: RUR-11-2016 | Award Amount: 1.99M | Year: 2017

The overall aim of AgriDemo-F2F is to enhance peer-to-peer learning within the commercial farming community. The project will utilize the experience of different actors and involve practitioner partners throughout the project to deepen understanding of effective on farm demonstration activities (multi-actor approach). In a first step, we will conduct a geo-referenced inventory of open commercial farms that engage in demonstration activities in Europe, detailing the sectors, themes and topics on which they provide expertise, and describe the mediation techniques they apply. Case studies will be selected to perform an in-depth comparative analysis. Important dimensions in selection are: 1) a wide-spread geo-graphical coverage within Europe, 2) representative for EU-agricultural sectors, systems and territories and 3) low tech versus high tech in mediation techniques. Case studies will be described, analysed and compared on 1) their network structure (actors, roles and governance characteristics), and 2) the mechanisms and tools used for recruitment, interaction and learning. Furthermore, effectiveness of the different approaches within the case-studies will be assessed through an evaluation of the extent and nature of learning. Both regional and international multi-actor meetings will use the results of the cross comparative case study analysis to i) identify a set of best practical approaches for both the on farm demonstration of research results (science driven) and the spreading of best farming practices among practitioners (innovation driven) and ii) recommendations for AKIS governance and policies on how to support effective on farm demonstration activities. The empowerment of both the commercial farming and policy community to uptake these best practices will occur through structuring the project results and farm demo showcases on the AgriDemo-Hub, an interactive, user oriented, web-map application.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: ICT-03-2016 | Award Amount: 3.89M | Year: 2017

MADIA aims at realizing a versatile and cheap diagnostic device based on magnetoresistive sensors, microfluidic device, ultrasmall Magnetic Nanoparticles (MNPs) and advanced bio-chemical functionalization methods for the early and ultrasensitive in vitro detection of biomarkers trustfully associated with 2 incurable neurodegenerative diseases: Alzheimers Disease (AD) and Parkinson Disease (PD). We plan to achieve sensitivities at least three orders of magnitude higher than best state-of-the-art values flexibility to operate for a wide range of concentrations. WHY: Neurodegenerative diseases (ND) are debilitating and largely untreatable conditions that are strongly linked with age. Amongst these disorders, the dementias are responsible for the greatest burden of disease, with Alzheimers disease and related disorders affecting some 7 million people in Europe. The current costs of the order of 130 billion per annum to care for people with dementia across Europe highlight age-related neurodegenerative disease as one of the largest medical and societal challenges faced by our society. PD is the second most common neurodegenerative disorder worldwide after AD. WHAT: The operation principle behind the proposed tool embodies a Magnetic Sensor Assay approach and consists of recognizing the targeted core and downstream biomarkers obtained from body fluids (such as cerebrospinal fluid - CSF and blood) through their complexation with nano-magnetic labels (MNPs) followed by a highly sensitive magnetic detection at micro-scales. The specific recognition of the protein by the magnetic nanoparticles will be achieved and ensured via protein bonding to functionalizing groups grafted on the surface of the MNP. The complexes MNP-BM will be injected into microfluidics channels flowing in the close vicinity of magnetic sensors, bringing thus the MNP-BM to distances where the magnetic field of the MNP will trigger a quantitatively detectable sensor response.

Loading University of Santiago de Compostela collaborators
Loading University of Santiago de Compostela collaborators